To address some of theselimitations, we took advantage of recent advances in growing and immortalizingmemory B cells in culture [35], [36], increased the number of patients evaluated, anddeveloped a novel screening tool to specifically detect tumor-reactive antibodiesagainst cell surface antigens on melanoma cells. The gene discussed is CD53; the disease is neoplasm.